CareDx, Inc. (NASDAQ:CDNA)
| Market Cap | 3.22B+321.2% |
| Revenue (ttm) | 458.09M+34.4% |
| Net Income | 111.01M+114.8% |
| EPS | 2.07+103.1% |
| Shares Out | 51.73M |
| PE Ratio | 28.95 |
| Forward PE | 48.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 449,772.856 |
| Open | 61.40 |
| Previous Close | 63.04 |
| Day's Range | 61.19 - 63.23 |
| 52-Week Range | 13.95 - 72.51 |
| Beta | 2.38 |
| Analysts | Buy |
| Price Target | 62.25(-0.06%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CDNA
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CDNA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CDNA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CDNA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CDNA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CDNA Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CDNA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CDNA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CDNA
| ETF | Est. Holding Size |
|---|---|
| ARKGARK Genomic Revolution ETF | $90.65M |
| XBIState Street SPDR S&P Biotech ETF | $88.28M |
| IWMiShares Russell 2000 ETF | $85.00M |
| VTIVanguard Morningstar Total Stock Market ETF | $77.99M |
| IWOiShares Russell 2000 Growth ETF | $30.25M |
| VXFVanguard Extended Market ETF | $30.10M |
Estimated from each fund’s disclosed top holdings × AUM
CDNA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CDNA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score